Based on the above-mentioned knowledge, we run this study to investigate the therapeutic efficacy and safety of nitazoxanide and escitalopram as adjuvant therapies in patients with RA, focusing on their effects on the STAT-3/JAK-2 and TLR-4/IL-1β signaling pathways, as well as oxidative stress modulation. This evidence concerns the gene STAT3 and rheumatoid arthritis.